REGN May 2024 860.000 call
| Previous close | 47.20 |
| Open | 47.20 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 860.00 |
| Expiry date | 2024-05-17 |
| Day's range | 47.20 - 47.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 18 |
ZacksDown -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround
Regeneron (REGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
ZacksCountdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Regeneron (REGN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
GlobeNewswireEYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and certain diabetic eye diseasesTARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA® HD (aflibercept) Injection 8 mg. The presentat
